This week, we will discuss the 2024 KDIGO Guidelines on CKD, part 1. In this section we will discuss the first two chapters on CKD evaluation and risk stratification. Let’s dive in!
This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
This week, we will discuss CONVINCE, a randomized controlled trial, about the long-lasting battle between hemodialysis and hemodiafiltration. Will it convince the unconvinced, or will it diffuse even more uncertainty into community?
This week, we will discuss the NOSTONE trial. Another renal reversal that will be practice changing. Should we stop using HCTZ for kidney stone prevention.
In this edition of NephTrials, we will discuss the bewildering world of master protocols, comprising of platform, umbrella and basket trials - with the example of the RENAL LIFECYCLE trial.
This week, we will discuss NEFIGARD, the trial of a targeted release steroid. It reduces proteinuria in IgA nephropathy - should it upstage humble prednisone?
This week, we will discuss the MYTEMP trial from Lancet. A cool idea, a cool cluster design. Warmly embraced by the Ontario dialysis community. But did it work?
This week, we will discuss the first new BP lowering drug in decades. Aprocitentan, a dual endothelin antagonist in a meticulously designed trial in resistant hypertension.
This week, we will discuss the STOP ACEi trial, a poster from Kidney Week but published in the NEJM. Should we stop RAS inhibition at an arbitrary GFR or bravely carry on?